Last reviewed · How we verify

22nd Century Group, Inc. — Portfolio Competitive Intelligence Brief

22nd Century Group, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Nicotine gum (C) Nicotine gum (C) marketed Nicotinic acetylcholine receptor agonist Nicotinic acetylcholine receptors Addiction Medicine / Smoking Cessation

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. GlaxoSmithKline · 1 shared drug class
  3. Instituto Fernandes Figueira · 1 shared drug class
  4. Iowa City Veterans Affairs Medical Center · 1 shared drug class
  5. Johns Hopkins University · 1 shared drug class
  6. Medical University of Vienna · 1 shared drug class
  7. Ottawa Hospital Research Institute · 1 shared drug class
  8. University of Auckland, New Zealand · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for 22nd Century Group, Inc.:

Cite this brief

Drug Landscape (2026). 22nd Century Group, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/22nd-century-group-inc. Accessed 2026-05-16.

Related